Sign In
Buy NLTX
$3.49
+0 (+0%)
At Close: Mar 15, 2024
Neoleukin Therapeutics (NASDAQ:NLTX) & Zymeworks (NASDAQ:ZYME) Critical Contrast
01:24am, Monday, 06'th Apr 2026
Neoleukin Therapeutics (NASDAQ: NLTX - Get Free Report) and Zymeworks (NASDAQ: ZYME - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two
Reviewing Intellipharmaceutics International (OTCMKTS:IPCIF) & Neoleukin Therapeutics (NASDAQ:NLTX)
01:24am, Sunday, 01'st Feb 2026
Valuation and Earnings This table compares Neoleukin Therapeutics and Intellipharmaceutics International"s revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income E
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
07:00pm, Thursday, 14'th Dec 2023
SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
08:00am, Friday, 22'nd Sep 2023
SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics
Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc
08:34pm, Thursday, 27'th Jul 2023
San Francisco-based investment firm, Redmile Group, LLC (Trades, Portfolio), recently increased its holdings in Neoleukin Therapeutics Inc ( NLTX , Financial), a biopharmaceutical company based in the
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Neoleukin
MILWAUKEE , July 18, 2023 /PRNewswire/ -- Ademi LLP is investigating Neoleukin (Nasdaq: NLTX) for possible breaches of fiduciary duty and other violations of law in its private placement and its trans
NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders
07:16am, Tuesday, 18'th Jul 2023
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) and Neurogene Inc. is fair to Neoleukin sha
Neurogene and Neoleukin Announce Definitive Merger Agreement
06:30am, Tuesday, 18'th Jul 2023
NEW YORK and SEATTLE, July 18, 2023 (GLOBE NEWSWIRE) -- Neurogene Inc., a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological
Neoleukin Therapeutics: Strategic Review Play
04:04am, Wednesday, 19'th Apr 2023
Neoleukin Therapeutics: Strategic Review Play
Neoleukin (NLTX) Up 36% on Initiating Another Restructuring Plan
12:15pm, Friday, 10'th Mar 2023
Neoleukin (NLTX) seeks strategic options to maximize shareholder's value. This includes the undertaking of another restructuring plan to reduce 70% of the existing workforce.
Shares of Neoleukin Therapeutics spike after announcing layoffs and potential sale or merger
10:21am, Thursday, 09'th Mar 2023
Neoleukin Therapeutics is slashing its workforce by about 70% as it seeks “strategic alternatives” for its future, according to a company statement Wednesday.
Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down
12:02pm, Wednesday, 16'th Nov 2022
Due to discontinuing the development of its lead candidate, Neoleukin (NLTX) has no pipeline candidates in clinical development. Management undertakes restructuring initiatives to curb cash burn.
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2022 Results - Earnings Call Transcript
12:55am, Wednesday, 10'th Aug 2022
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Julie Rathbun - Investor Relations Jonathan Drachman - Chief Executive Offic
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
08:00am, Wednesday, 27'th Jul 2022
SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 af
